OPSYON Therapeutics

OPSYON Therapeutics is a pioneering biotechnology research company dedicated to developing innovative immunotherapies for the treatment of cancer. OPSYON Therapeutics focuses on combining immune checkpoint inhibition with antibody-based tumor targeting to create novel multifunctional therapeutic antibodies. The company's approach aims to provide cancer patients with effective therapies that offer reduced systemic side effects and the potential for long-term survival, ultimately improving their quality of life. Located in München, DE, OPSYON Therapeutics is committed to advancing the field of cancer treatment through cutting-edge research and development.

OPSYON Therapeutics’s molecules are designed with a unique dock and block mechanism, featuring a tumor-specific antibody fused to a domain that binds to CD47, effectively blocking its interaction with SIRPa and inhibiting the ‘don't eat me’ signal. This targeted approach ensures that CD47 blocking occurs with low affinity only when the antibody has previously bound to its target on tumor cells, thereby minimizing side effects associated with systemic CD47 inhibition. OPSYON Therapeutics utilizes an IgG1 antibody, leveraging the full spectrum of immune cells, including NK-cells, monocytes/macrophages, and T-cells, to facilitate both direct tumor cell elimination and a prolonged anti-tumor response.

With a lead candidate, OPS-121, targeting acute myeloid leukemia (AML), OPSYON Therapeutics has developed a robust data package that demonstrates efficacy, an improved safety profile, and promising manufacturability and stability. Additionally, OPSYON Therapeutics is advancing OPS-301, a pipeline candidate targeting solid tumors such as pancreatic and ovarian cancer. OPSYON Therapeutics is dedicated to transforming cancer treatment by enhancing effectiveness, reducing side effects, and ultimately improving outcomes for cancer patients. To the manager of OPSYON Therapeutics: We invite you to create a customized and exclusive company showcase and product listing on our platform.